US4985233A - A diagnostic agent containing a non-radioactive paramagnetic metal species in a macromolecular carrier - Google Patents

A diagnostic agent containing a non-radioactive paramagnetic metal species in a macromolecular carrier Download PDF

Info

Publication number
US4985233A
US4985233A US06/793,899 US79389985A US4985233A US 4985233 A US4985233 A US 4985233A US 79389985 A US79389985 A US 79389985A US 4985233 A US4985233 A US 4985233A
Authority
US
United States
Prior art keywords
particles
water
distilled water
suspension
paramagnetic metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/793,899
Other languages
English (en)
Inventor
Jo Klaveness
Trond Jacobsen
Bernt J. Lindberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE8405500A external-priority patent/SE465908B/sv
Priority claimed from SE8405501A external-priority patent/SE465909B/sv
Application filed by Nycomed AS filed Critical Nycomed AS
Assigned to NYEGAARD & CO. A/S, A NORWEGIAN BODY CORPORATE reassignment NYEGAARD & CO. A/S, A NORWEGIAN BODY CORPORATE ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: JACOBSEN, TROND, KLAVENESS, JO, LINDBERG, BERNT J.
Application granted granted Critical
Publication of US4985233A publication Critical patent/US4985233A/en
Assigned to NYCOMED IMAGING AS reassignment NYCOMED IMAGING AS CERTIFICATE OF REGISTRATION REFLECTING CHANGE OF NAME Assignors: NYCOMED AS
Assigned to NYCOMED AS reassignment NYCOMED AS CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NYEGAARD & CO AS
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/12Macromolecular compounds
    • A61K49/126Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/806Electrical property or magnetic property
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Definitions

  • the present invention relates to a diagnostic agent containing a paramagnetic metal species, which diagnostic agent is for use in diagnosis based on NMR (Nuclear Magnetic Resonance) and ultrasound signals which are transformed into pictures over the examined area of a body of a human or non-human animal.
  • NMR Nuclear Magnetic Resonance
  • the signal intensity (or contrast in the NMR picture) depends strongly on the nuclear density, the relaxation times and the parameters of the instrument (pulse sequence, frequency, etc.).
  • Paramagnetic complexes for use in NMR diagnosis are also disclosed by EP-A-71564 and DE-A-34 01 052. These references describe chelate complexes formed from paramagnetic metal ions and various complex-forming agents containing organic nitrogen, phosphorus, oxygen and/or sulphur, primarily aminopolycarboxylic acids, e.g. ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA).
  • EDTA ethylenediaminetetraacetic acid
  • DTPA diethylenetriaminepentaacetic acid
  • Proteins are substances of very complicated structure and generally possess limited stability and applicability. Thus they are difficult to formulate into solutions and they should not be subjected to treatment by heat, which means that diagnostic agents containing proteins cannot be sterilized by the application of heat. The shelf life of such diagnostic agents will be limited and the proteins often exert an effect of their own which is not wanted in connection with the diagnostic investigation. The possibilities of choosing materials for different diagnostic purposes or materials with a desired way of excretion and a desired rate of elimination from the body of an animal (human or non-human) are also limited. Similar problems arise with the other bio-molecules suggested as paramagnetic metal carriers in EP-A-71564.
  • a water insoluble macromolecular material comprising a polymeric or polymerized carbohydrate or a polymerized sugar alcohol or derivative thereof.
  • a diagnostic agent containing a non-radioactive paramagnetic metal species characterized in that said agent comprises a physiologically tolerable, water-insoluble, hydroxyl group-containing macromolecular product in particulate form, said macromolecular product comprising at least one material selected from the group comprising polymeric and polymerized carbohydrates and polymerized sugar alcohols and derivatives thereof, and said macromolecular product serving as a carrier for at least one non-radioactive paramagnetic metal species.
  • the paramagnetic metal species in the diagnostic agent of the invention may be chemically bound to the macromolecular carrier or alternatively may be present in solid or liquid inclusions within the carrier product.
  • the carrier product particularly preferably comprises a material cross-linked to form a three-dimensional network swellable but insoluble in water. In the case of such swellable carrier products where the swellable products exhibit cavities these may conveniently be at least partially filled with at least one paramagnetic metal species-containing substance which is insoluble or only sparingly soluble in water.
  • the present invention thus provides diagnostic agents containing a paramagnetic metal species, which diagnostic agents are based on well documented polymer compounds of simple structures and which, for instance, can easily be formulated, have a good shelf life and are well tolerated.
  • the present invention thus also provides diagnostic agents containing a paramagnetic metal species, the distribution and elimination of which diagnostic agents within the body under investigation can easily be varied by the use of polymers of different structures.
  • the term "polymeric carbohydrate” is used herein to designate a naturally occurring polymer built up of carbohydrate monomers while the term “polymerized carbohydrate” is used to designate a synthetic polymer obtained by polymerizing carbohydrate molecules, e.g. with the aid of at least bifunctional coupling or cross-linking agents.
  • polymerized sugar alcohol is used to designate a synthetic polymer obtained by polymerizing sugar alcohol molecules, e.g. with the aid of at least bifunctional coupling or cross-linking agents.
  • paramagnetic metal species as used herein includes within its scope both paramagnetic atoms and ions.
  • the macromolecular product is preferably a material which is insoluble but swellable in water.
  • water-soluble polymeric or polymerized carbohydrates or polymerized sugar alcohols or derivatives thereof can be cross-linked with the aid of cross-linking agents which are least bifunctional to a practically endless three-dimensional network which is held together by bonds of covalent character and which is insoluble but swellable in water and aqueous media.
  • cross-linking polysaccharides e.g. dextran, starch, agarose and other polymeric carbohydrates and derivatives thereof
  • gel particles preferably in bead form
  • ether bonds or ester bonds e.g. carboxylic acid ester bonds, carbamic acid ester bonds, thiocarbamic acid ester bonds, etc.
  • ether-bound crosslinking bridges and ester-bound cross-linking bridges and methods for the production of such gel particles are for example described in GB-A-1 518 121, U.S. Pat. No. 4,225 580, GB-A-1 251 433, U.S. Pat. Nos. 3,042,667 and 3,002 823.
  • the molecules of the polysaccharide or of the derivative thereof etc. are cross-linked by bridges bound to these molecules by ether bonds, wherein between the ether bonds the bridges may advantageously be straight or branched aliphatic saturated hydrocarbon chains which are substituted by one or more hydroxyl groups (e.g. one to six hydroxyl groups), which contain 3-30 carbon atoms, preferably 3-20 carbon atoms, and especially 3-10 carbon atoms, and which optionally are interrupted by one or more oxygen atoms (e.g. one to six oxygen atoms).
  • hydroxyl groups e.g. one to six hydroxyl groups
  • oxygen atoms e.g. one to six oxygen atoms
  • n is an integer, for example an integer from 2 to 4.
  • the molecules of the polysaccharide or of the derivative thereof are cross-linked by bridges bound to said molecules by ester bonds (which preferably are carboxylic acid ester bonds, but which for example may also be carbamic acid ester bonds or thiocarbamic acid ester bonds), the bridges between the ester bonds advantageously being straight or branched aliphatic saturated hydrocarbon chains containing 2-20 carbon atoms, preferably 2-10 carbon atoms such as 2-6 carbon atoms, optionally being interrupted by one or more oxygen atoms (e.g. one to six oxygen atoms), and optionally being substituted with one or more hydroxyl groups (e.g. one to six hydroxyl groups).
  • ester bonds which preferably are carboxylic acid ester bonds, but which for example may also be carbamic acid ester bonds or thiocarbamic acid ester bonds
  • the bridges between the ester bonds advantageously being straight or branched aliphatic saturated hydrocarbon chains containing 2-20 carbon atoms, preferably 2-10 carbon atom
  • ester-bound (in its widest significance) cross linking bridges examples include --O--CO--(CH 2 ) n .sbsb.1 --CO--O-- (where n 1 is an integer, for example an integer from 1 to 20, preferably 2-10, especially preferably 2 to 6), --O--CO--CH 2 --O--CH 2 --CO--O--, --O--CO--NH--(CH 2 ) n .sbsb.2 --NH--CO--O--- and --O--CS--NH--(CH 2 ) n .sbsb.2 --NH--CS--O (where n 2 is an integer, for example an integer from 2 to 6).
  • non-cross-linked macromolecular products useful according to the invention include cellulose, agarose and other insoluble polysaccharides and insoluble derivatives thereof. These can be used e.g. in the preparation of diagnostic agents for administration to body cavities having external escape ducts, e.g. the bladder, the uterus and the gastrointestinal tract.
  • the cross-linked macromolecular product can be obtained in the form of particles either by preparing the polymerisates in the form of larger pieces (bulk polymerization) and then disintegrating said pieces, for instance by grinding, or by directly preparing the product in the form of smaller, preferably spheroidal, particles (beads) by dispersion polymerization. Particles of the desired size range can be isolated by fractionation of the product, e.g. by sieving.
  • the particle size chosen will vary depending on the particular use intended for the diagnostic agent. In general, however, the particles in their water-swollen state will have a size within the range 0.01-1000 ⁇ m, preferably within the range 0.1-100 ⁇ m. In this connection, particles having a particle size within the range 0.01-5 ⁇ m, such as eg within the range of 0.1-3 ⁇ m, are considered small, whereas particles having particle size exceeding 5 ⁇ m, for instance having a particle size within the range 5-100 ⁇ m, are considered large. For parenteral use small particles, preferably particles having a particle size less than 3 ⁇ m, should be used where it is intended that the particles should be able to pass blood capillaries without causing obstruction.
  • particles having a size within a wide range can be used. However, in order to avoid sedimentation of the particles, it is preferred that particles of a size less than 10 ⁇ m be used.
  • the swellability of the product in water and aqueous media can be varied by varying the cross-linking agent and/or the degree of crosslinking.
  • the swellability is preferably chosen such that the particles of the macromolecular product in water-swollen state contain 10-98, preferably 15-95, and especially preferably 20 to 90, percent by weight of water.
  • Examples of basic materials which may be crosslinked to water-insoluble but water-swellable gel particles include water soluble polysaccharides such as glucans, e.g. starch, amylose, amylopectin (including macromolecular dextrins thereof), glycogen, dextran and pullulan, fructans, e.g. inulin and levan, and other physiologically tolerable polysaccharides of vegetable, microbial or animal origin.
  • Another example is the so called polyglucose obtained by polymerization of glucose.
  • Ohter examples include macromolecular products obtained by cross-linking carbohydrates or sugar alcohols (e.g. mannitol and sorbitol) with at least one bifunctional cross-linking agent, e.g.
  • the gel particles are suitable for being provided with paramagnetic metal containing substances.
  • the macromolecular product in the particles in the diagnostic agent of the invention is chosen according to the agent's intended use.
  • insoluble particles which are not degradable in the body may be chosen for investigation of body cavities having outward escape ducts (e.g. the gastro-intestinal tract, the bladder and the uterus).
  • Insoluble particles which are degradable in the body to smaller, water-soluble excretable fragments may be chosen, for example, for parenteral administration.
  • the macromolecular product in the particles may be enzymatically degradable by hydrolases, e.g. endohydrolases, which hydrolyze glycosidic linkages in the macromolecular product.
  • macromolecular products which are degradable by ⁇ -amylase are chosen.
  • cross-linked, insoluble macromolecular products based on starch or other polysaccharides degradable by ⁇ -amylase and degradable derivatives thereof can be used.
  • the total degree of substitution of such starch derivatives should however not be chosen to be so high as to stop the derivative being degradable, generally the average degree of substitution will often be less than 0.6 and preferably will be less than 0.5 (i.e. less than one substituent per 2 glucose units), for example less than 0.3 or 0.2 or 0.1.
  • particles consisting of such macromolecular products are degraded in the body, smaller, water-soluble fragments (some of which may contain the paramagnetic metal species) are formed and these fragments can be excreted with the urine.
  • Particles based on cross-linked starch which are degradable by ⁇ -amylase are described e.g. in GB-A-1 518 121.
  • the particles can be produced with the desired size and, if desired, can be provided with metal binding structures to which the paramagnetic metal species may be chemically bound.
  • degradable particles according to the invention having such a size e.g.
  • RES reticuloendothelial system
  • the macromolecular product particles in the diagnostic agent of the invention may be neutral or may have a negative or positive net charge in aqueous suspensions.
  • particles with no net charge or a negative net charge in aqueous suspensions are preferred.
  • a negative net charge may be obtained for instance by introducing carboxyl groups or other negatively charged groups into the macromolecular product if such groups are not already present in the macromolecular product.
  • the non-radioactive paramagnetic metal is preferably selected from the group of elements having atomic numbers 21-29, 42, 44 and 57-70, elements having atomic numbers 24-29 or 62-69 being especially preferred.
  • suitable lanthanides include gadolinium, europium, dysprosium, holmium and erbium.
  • suitable elements include manganese, iron, nickel, chromium and copper.
  • the paramagnetic metal species may in one embodiment of the invention be chemically bound in the macromolecular product.
  • the polymeric or polymerized carbohydrate or the polymerized sugar alcohol or derivative thereof used in the preparation of the diagnostic agent of the invention contains or may be provided with binding structures to which the paramagnetic metal species may be bound. It is well known that many structures bind metals of the types which are of interest in this connection. Such structures are easily introduced into polymeric or polymerized carbohydrates or polymerized sugar alcohols or derivatives thereof if not already present in these macromolecules. For example, several such insoluble products have been used for extracting heavy metal ions from aqueous solutions and for binding metallic radionuclides.
  • structures to which the metal species is bound in a complex can be used; structures wherein the metal species is bound in a chelate complex being preferred.
  • Many groups are known which bind metal ions in chelate complexes in which complexes the metal can be included e.g. in a 4-, 5- or 6-membered ring comprising said metal and two metal-coordinating atoms.
  • the chelate complex comprises at least two 5- or 6-membered rings comprising the metal, especially four to eight 5- or 6-membered rings.
  • Such 5- and 6-membered rings comprise the metal and two metal-coordinating atoms, separated from each other by two or three atoms respectively
  • one of the metal-coordinating atoms is preferably a nitrogen atom and the other a nitrogen atom, a sulphur atom or an oxygen atom.
  • the nitrogen atom can, for instance, be the nitrogen atom in an amino, imino or nitrilo group.
  • the sulphur atom can, for instance, be the sulphur atom in a mercapto, thioether or thiono group.
  • the oxygen atom can, for instance, be an oxygen atom in a keto, carboxylate, sulphonate, sulphate, phosphonate, phosphate, nitrate, hydroxyl or ether group.
  • the metal-coordinating atoms are members of chelate-forming groups which preferably contain at least two sequences, which may be equal or different, and which, in addition to the metal-coordinating atoms, preferably contain 2 or 3 carbon atoms (in the case of 5- and 6-membered rings respectively) in the chelate complex, one of the carbon atoms optionally being replaced by an oxygen, sulphur or nitrogen atom.
  • the chelate-forming groups may have the general formula ##STR1## wherein n is 2 or 3, m is an integer 1, 2, 3 or higher, generally lower than 1000, e.g.
  • R 1 , R 2 and R 3 which may be equal or different, each represents a hydrogen atom or a group --CH 2 --COOH or --CH 2 --CH 2 --COOH.
  • the carboxymethyl and the carboxyethyl groups may be replaced by sulphomethyl phosphomethyl or aminoethyl groups or by sulphoethyl, phosphoethyl or aminopropyl groups respectively, or by other equivalent groups.
  • the chelate-forming groups may of course be used in salt form.
  • the chelate-forming groups may be covalently bound to hydroxyl groups of the polymeric or polymerized carbohydrate or polymerized sugar alcohol or derivative thereof, e.g. by methods known per se. For instance, when using an aminopolycarboxylic acid, such as ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), triethylenetetraaminehexaacetic acid (TTHA) or N-hydroxyethylethylenediaminetriacetic acid (HEDTA), to establish chelate-forming groups, a carboxylic group of said acids may be utilized to produce an ester bond to the basic molecule of the macromolecular product by reaction, e.g.
  • an aminopolycarboxylic acid such as ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), triethylenetetraaminehexaacetic acid (TTHA) or N-hydroxyethylethylenediaminetriacetic acid
  • anhydrides or acid halides of such polycarboxylic acids can also be used.
  • an amino-polycarboxylic acid containing a primary or secondary amino group can be reacted with a macromolecular substance containing carboxylic groups in order to form an amide bond, e.g. by using conventional methods for establishing such bonds.
  • Reactive groups may also be introduced into the basic molecule of the macromolecular product, e.g. a polysaccharide, for example in ways known per se; such reactive groups can then be reacted with thiol or amino groups or other nucleophilic moieties in the substance used for the introduction of chelate-forming groups.
  • groups are aldehyde and keto groups, halogenoacetyl, azide, isocyanate, isothiocyanate, s-triazinyl and divinylsulphone groups, carbonic acid ester groups, imidocarbonic acid ester groups (formed by cyanogen bromide activation), oxirane groups and groups which are easily converted to oxirane derivatives and reactive disulphides.
  • activation of hydroxyl groups of the basic molecule of the macromolecular product with a base will enable a reaction with electrophilic moieties in the substance used for the introduction of chelate-forming groups to occur.
  • the complete chelate-forming group may be bound directly to the basic molecule of the macromolecular product or may be built up successively by binding a starting material for said group to said basic molecule and then modifying said starting material chemically.
  • a compound of the general formula H 2 N--[(CH 2 ) n--NH] m --H, wherein m and n are as defined above may first be bound to said basic molecule, e.g. by methods known per se, whereafter the amino groups can be carboxymethylated or carboxyethylated to the desired extent.
  • a bridging group can be introduced between the chelate-forming groups and the basic molecule of the macromolecular product, e.g. in a manner known per se.
  • the paramagnetic metal can for example be bound to the macromolecular product by reacting the intermediate macromolecular substance containing chelate-forming groups with an excess of a watersoluble salt of the paramagnetic metal in aqueous solution at an appropriate pH-value, usually 2-7, e.g. 5-6.
  • the paramagnetic metal species may be present in cavities within the macromolecular product, in the form of an insoluble or sparingly soluble substance or composition.
  • the incorporation of the paramagnetic metal species within the macromolecular carrier product can be achieved in several ways.
  • dry or incompletely water-swollen particles of a swellable macromolecular product may be swelled in a solution, preferably an aqueous solution, of a salt of the paramagnetic metal, for instance the chloride of said metal, whereafter the particles are dried.
  • the particles are then swelled again in a solution, preferably an aqueous solution, of a substance which is capable of precipitating the metal in the form of an insoluble or sparingly soluble material, compound or complex.
  • the precipitating substance may be a soluble phosphate, such as sodium phosphate, when the phosphate of the paramagnetic metal is insoluble or sparingly soluble in the medium in which the particles are swelled.
  • the precipitating substance may be an alkali metal hydroxide when the hydroxide of the paramagnetic metal is insoluble or sparingly soluble in the medium in which the particles are swelled.
  • dry or incompletely water swollen particles of a swellable macromolecular product are swelled in a solution comprising a solvent in which the particles swell, e.g. water or dimethylsulfoxide, and one or more reagents of which at least one comprises the paramagnetic metal species in a suitable chemical form, and which reagents (optionally in contact with the macromolecular product) produce by a chemical reaction (which may involve the macromolecular product), for example a redox process, the metal species in elemental state or in the state of an insoluble or sparingly soluble chemical compound containing the metal, said metal or compound being finely dispersed in the cavities of the macromolecular product.
  • a solvent in which the particles swell e.g. water or dimethylsulfoxide
  • reagents of which at least one comprises the paramagnetic metal species in a suitable chemical form
  • reagents optionally in contact with the macromolecular product
  • a chemical reaction
  • the preparation of the macromolecular product is prepared by a process involving a cross-linking reaction carried out in a medium in which microparticles of the paramagnetic metal or a compound or complex thereof are dispersed, said compound or complex being insoluble or sparingly soluble in said medium.
  • the paramagnetic metal species will become entrapped in a very finely dispersed form in cavities formed in the three-dimensional network of the particles of the macromolecular product.
  • paramagnetic metal species is incorporated as a complex
  • this is preferably a chelate complex which is insoluble or sparingly soluble in aqueous media.
  • such a chelate complex comprises at least two 5- or 6-membered rings comprising the metal, especially four to eight 5- or 6-membered rings.
  • Such 5- and 6-membered rings comprise the metal and two metal-coordinating atoms, separated from each other by two or three atoms respectively.
  • One of the metal-coordinating atoms is preferably a nitrogen atom and the other a nitrogen atom, a sulphur atom or an oxygen atom.
  • the nitrogen atom can, for instance, be the nitrogen atom in an amino, imino or nitrilo group.
  • the sulphur atom can, for instance, be the sulphur atom in a mercapto, thioether or thiono group.
  • the oxygen atom can, for instance, be an oxygen atom in a carboxylate, sulphonate, sulphate, keto, phosphonate, phosphate, nitrate, hydroxyl or ether group.
  • the metal-coordinating atoms are members of chelate-forming groups which preferably contain at least two sequences, which may be equal or different, which in addition to the metal-coordinating atoms preferably contain 2 or 3 carbon atoms (in the case of 5- and 6-membered rings respectively) in the chelate complex, one of the carbon atoms optionally being replaced by an oxygen, sulphur or nitrogen atom.
  • the macromolecular product particles may in aqueous suspensions have a net charge in which case the diagnostic agent should include a physiologically acceptable counterion.
  • useful cations in this connection include sodium and potassium ions and the cations of non-toxic amines such as e.g. tris(hydroxymethyl)aminomethane, ethanolamine, diethanolamine and N-methylglucamine.
  • useful anions include chloride ions and the anions of non-toxic organic acids.
  • the diagnostic agent according to the invention may e.g. be in the form of a suspension of the macro-molecular product particles in an aqueous medium or may be in dry form, e.g. in the form of a powder or tablets to be used for the preparation of a suspension just before administration.
  • the agent may also be in the form of capsules or coated tablets to be administered orally, in which case the coating of the tablet or capsule is dissolved in the gastro-intestinal tract to release the macromolecular product particles. Uncoated tablets, which are disintegrated in the gastrointestinal tract may also be used for oral administration.
  • a suspension in a sterile physiologically acceptable medium is preferably used, e.g. an isotonic aqueous solution.
  • a suspension in a physiologically acceptable medium e.g. an aqueous suspension, optionally containing viscosity-increasing substances may conveniently be used.
  • the aqueous suspension may be adjusted to the desired pH-value by means of a physiologically acceptable buffer.
  • the diagnostic agents according to the present invention may conveniently be formulated to contain at least one pharmaceutical carrier or excipient, and may optionally contain viscosity enhancing agents, osmolality regulators, colouring agents, flavouring agents or dispersants.
  • the concentration of the paramagnetic metal in the diagnostic agent will be dependent on the administration form and on the particular organs or tissues to be studied. Generally the total dosage will be in the range of 10 -6 to 10, preferably about 10 -3 to 10 -1 , mmol of the paramagnetic metal species per kg bodyweight.
  • the paramagnetic metal content of the macromolecular product will generally be 0.001-30 percent by weight, preferably more than 0.01 percent by weight, e.g. more than 0.1 per cent by weight, and, for example, lower than 20 percent by weight or lower than 10 percent by weight, calculated on the total weight of the macro-molecular product in dry substance form.
  • the concentration of the macromolecular product in a suspension to be used in NMR or ultrasound diagnosis will generally be higher than 0.01 per cent by weight, for instance higher than 0.1 per cent by weight, for example higher than 1 per cent by weight, and lower than 35 percent by weight, for example lower than 25 percent by weight, e.g. lower than 15 percent by weight, calculated on the total weight of the suspension.
  • the concentration may conveniently be within the range 0.1-10 percent by weight, calculated on the total weight of the suspension. (The weight of the macromolecular product is that of the dry substance.)
  • the diagnostic agent according to the invention can be used in NMR imaging because the paramagnetic metal species carried by the macromolecular product reduces the relaxation times. It can also be used in NMR examinations due to its effect on the chemical shifts or it can be used in ultrasound examinations due to its effect on sound velocity.
  • a method of diagnosis which method comprises administering to a human or non-human animal body or to a selected region thereof a contrast effective amount of the diagnostic agent of the invention and generating an NMR or ultrasound image of said body or said region.
  • a method of producing an image capable of use in diagnosis which method comprises administering to a human or non-human animal body or to a selected region thereof a contrast effective amount of the diagnostic agent of the invention and generating an NMR or ultrasound image of said body or said region, and optionally fixing said image in hard-copy form, e.g. in printed graphic or in photographic negative or positive form.
  • a process for the preparation of a water-insoluble, paramagnetic metal species-containing macromolecular material comprising chemically binding a non-radioactive paramagnetic metal species to or trapping or depositing a non-radioactive paramagnetic metal species in a water-insoluble or sparingly soluble form within a physiologically tolerable, water-insoluble, particulate macromolecular product comprising at least one material selected from the group comprising polymeric and polymerized carbohydrates and polymerized sugar alcohols and derivatives thereof.
  • a process for preparing a diagnostic agent containing a non-radioactive paramagnetic metal species characterized in that said process comprises admixing with a least one pharmaceutical carrier or excipient a physiologically tolerable, water-insoluble, hydroxyl group-containing macromolecular product in particulate form, said macromolecular product comprising at least one material selected from the group comprising polymeric and polymerized carbohydrates and polymerized sugar alcohols and derivatives thereof.
  • a diagnostic agent for use in a method of diagnosis practised on the human or animal body of a non-radioactive paramagnetic metal species and a physiologically tolerable, water-insoluble, hydroxyl-group containing, particulate macromolecular product comprising at least one material selected from the group comprising polymeric and polymerized carbohydrates and polymerized sugar alcohols and derivatives thereof.
  • DOTA 1,4,7,10-tetraazacyclododecane - N,N',N",N'" tetraacetic acid
  • DTPA diethylenetriaminepentaacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • TTHA triethylenetetraaminehexaacetic acid
  • T 1/2 half life by ⁇ -amylase degradation
  • T 1 spin lattice relaxation time
  • Starch particles in the form of gel beads with various average diameters, half-lifes (T 1/2 ) in 240 IU/l of ⁇ -amylase at pH 7.0 and 37° C. and water regain (W r ) were prepared by cross-linking hydrolyzed potato starch with epichlorohydrin using the method described in GB-A-1251433 and U.S. Pat. No. 4,126,669. The products were analyzed as described in those patents. In the following Examples particles with the following characteristics were used:
  • W r is defined as the weight of water (g) taken up by 1 g of dry particles. The percentage of water within the swelled particle is ##EQU1##
  • the particles were suspended in 50 ml distilled water, the pH-value was adjusted to 6.2 and a solution of 0.92 g FeCl 2 .4H 2 O in 10 ml distilled water was added during agitation. The pH-value was adjusted to 5.1 and the suspension was agitated for 2 hours.
  • the particles were isolated by centriguation, washed with distilled water, dialyzed with 0.9 per cent (w/v) NaCl until the solutions were free from paramagnetic compounds (about 5 days), washed with distilled water and dried in vacuo at 50° C.
  • SRRE Specific relaxation rate enhancement
  • DTPA was bound to 2.0 g starch gel beads (Example 1, type A) as described in Example 2.
  • the particles were suspended in 50 ml distilled water.
  • the pH-value was adjusted to 6.1 and a solution of 1.15 g CuSO 4 .5H 2 O in 10 ml distilled water was added during agitation, the pH-value was adjusted to 5.2 and the suspension was agitated for 1 hour.
  • the particles were purified and isolated as described in Example 2. 1.2 g of blue green particles containing 8.1 percent (w/w) Cu were obtained. W r 7.9. T 1/2 >24 h.
  • SRRE 0.12 s -1 mM -1 . D 25-70 ⁇ m (90 percent within the given range).
  • DTPA was bound to 0.30 g starch gel beads (Example 1, type A) as described in Example 2 by using 0.50 g of the bisanhydride of DTPA.
  • the particles were suspended in 30 ml of distilled water, the pH-value was adjusted to 5.8 and a solution of 0.20 g GdCl 3 .6H 2 O in 20 ml distilled water was added during agitation. The pH-value was adjusted to 5.8 and the suspension was agitated for 1 hour.
  • the particles were purified and isolated as described in Example 2. 0.25 g of white particles containing 1.5 percent (w/w) Gd was obtained. The particles swell in water. T 1/2 1 h.
  • DTPA was bound to 2.0 g starch gel beads (Example 1, type A) as described in Example 2.
  • the particles were suspended in 50 ml distilled water, the pH-value was adjusted to 6.2 and a solution of 1.77 g ErCl 3 (containing 40 percent of water) in 10 ml distilled water was added during agitation, the pH-value was adjusted to 5.1 and the suspension was agitated for 30 minutes.
  • the particles were purified and isolated as described in Example 2. 1.77 g of white particles containing 8.5 percent (w/w) Er were obtained. W r 9.6. T 1/2 6 h. SRRE 0.11 s -1 mM -1 . D 30-100 ⁇ m (90 percent within the given range).
  • 1.0 g starch gel beads (Example 1, type A) was swelled in 15 ml distilled water, 1.0 ml epichlorohydrin and 3.5 ml 2M NaOH were gradually added during 2 hours while the suspension was shaken at ambient temperature. 6 mg sodium borohydride were added and the suspension was shaken for 24 hours at ambient temperature. The particles were collected on a filter, washed on the filter with distilled water and resuspended in 25 ml distilled water. 2.4 g of 1,6-diaminohexane were added and the suspension was shaken for 22 hours at ambient temperature. The particles were collected on a filter and washed on the filter with distilled water.
  • the particles were resuspended in 30 ml distilled water. 4.8 g of the bisanhydride of DTPA were added and the suspension was shaken for 17 hours at ambient temperature. The pH-value was adjusted to 10, the particles were collected on a filter, washed thoroughly with distilled water and resuspended in 50 ml of distilled water. The pH-value was adjusted to 6.0, a solution of 0.5 g GdCl 3 .6H 2 O in 20 ml distilled water was added and the pH-value was adjusted to 5.1. The suspension was shaken for 30 minutes, the particles were collected on a filter, washed thoroughly with distilled water and dried in vacuo at 50° C.
  • a solution of 1.83 g 1,1'-carbonyldiimidazole in 15 ml dry acetone was added to a suspension of 1.5 g starch gel beads (Example 1, type A) in 20 ml of dry acetone.
  • the suspension was shaken for 20 minutes at ambient temperature and the solvent was removed after centrifugation.
  • the particles were washed with acetone, resuspended in 50 ml acetone and 3.9 g 1,6-diaminohexane were added.
  • the suspension was shaken for 18 hours at ambient temperature, the solvent was removed after centrifugation and the particles were washed with acetone.
  • the particles were resuspended in dry dimethylformamide (DMF), 4.0 g of the bisanhydride of DTPA were added and the mixture shaken for 24 hours at ambient temperature. 100 ml of distilled water were added, the pH-value was adjusted to 10 and the suspension was agitated for 30 minutes at ambient temperature. The suspension was centrifuged, the supernatant was removed and the particles were thoroughly washed with distilled water. The particles were resuspended in 30 ml of distilled water, the pH-value was adjusted to 6.0 and a solution of 1.0 g GdCl 3 .6H 2 O in 20 ml distilled water was added.
  • DMF dry dimethylformamide
  • the pH-value was adjusted to 5.8 and the suspension was agitated for 30 minutes at ambient temperature followed by centrifugation. The supernatant was removed and the particles were thoroughly washed with distilled water. The particles were dried in vacuo at 50° C. 1.2 g of white particles containing 17.9 percent (w/w) Gd were obtained. The particles swell in water. T 1/2 >24 hours. On suspending 30 mg of the particles in 5 ml glycerol:water (1:2.13) (v:v), T 1 was reduced from 1926 ms to 380 ms. D av 45 ⁇ m.
  • starch gel beads (Example 1, type A) were suspended in 25 ml of dry acetone. 2.0 ml of triethylamine were added and the suspension was cooled to 0° C. A solution of 2.5 g p-toluenesulphonyl chloride in 6 ml dry acetone, cooled to 0° C., was added to the agitated suspension. The suspension was agitated for 1 hour at 0° C. and for 23 hours at 5° C. The suspension was centrifuged, the supernatant removed and the particles washed with cold acetone.
  • the particles were resuspended in 30 ml of dry methanol. 100 ml of a 5.3M solution of ammonia in methanol were added and the suspension was agitated for 20 hours at ambient temperature. The suspension was centrifuged, the supernatant was removed and the particles were washed with methanol. The particles were resuspended in 100 ml of dry DMF. 4.9 g of the bisanhydride of DTPA were added, the suspension was treated as in Example 7 and the resulting DTPA particles were resuspended in 100 ml distilled water, the pH-value was adjusted to 6.1 and a solution of 1.5 g GdCl 3 . 6H 2 O in 20 ml distilled water was added.
  • the pH-value was adjusted to 5.0 and the suspension was agitated for 30 minutes at ambient temperature followed by centrifugation. The supernatant was removed and the particles were thoroughly washed with distilled water. The particles were dried in vacuo at 50° C. 2.1 g of white particles containing 19.1 percent (w/w) Gd were obtained. The particles swell in water. T 1/2 >24 hours. On suspending 30 mg of the particles in 5 ml glycerol:water (1:2.13) (v:v), T 1 was reduced from 1926 ms to 455 ms. D av 45 ⁇ m.
  • the particles were resuspended in 80 ml dry acetone, 5.3 g of 1,6-diaminohexane were added and the suspension was agitated for 20 hours at ambient temperature. The suspension was centrifuged, the supernatant was removed and the particles were washed with dry acetone and treated with DTPA as in Example 8.
  • the pH-value of the DTPA-particle suspension was adjusted to 5.7 and a solution of 0.87 g GdCl 3 .6H 2 O in 20 ml of distilled water was added. The pH-value was adjusted to 5.1 and the suspension was treated and the particles isolated as in Example 8. 2.0 g of white particles containing 10.7 percent (w/w) Gd were obtained. The particles swell in water. T 1/2 >24 hours. On suspending 30 mg of the particles in 5 ml glycerol:water (1:2.13) (v:v), T 1 was reduced from 1926 ms to 479 ms. D av 1.5 ⁇ m.
  • DTPA was bound to 2.0 g starch gel beads (Example 1, type B) as described in Example 2.
  • the particles were suspended in 50 ml distilled water, the pH-value was adjusted to 6.1 and a solution of 1.23 g CrCl 3 .6H 2 O in 10 ml distilled water was added. The pH-value was adjusted to 5.0 and the suspension was agitated for 35 minutes.
  • the particles were purified and isolated as described in Example 2. 1.23 g of violet particles containing 4.0 percent (w/w) Cr were obtained. W r 4.7. T 1/2 >24 hours.
  • SRRE 0.91 s -1 mM -1 . D av 1.2 ⁇ m.
  • DTPA was bound to 2.0 g starch gel beads (Example 1, type B) as described in Example 2.
  • the particles were suspended in 50 ml distilled water, the pH-value was adjusted to 6.2 and a solution of 0.91 g MnCl 2 .4H 2 O in 10 ml distilled water was added, the pH-value was adjusted to 5.2 and the suspension was agitated for 40 minutes.
  • the particles were purified and isolated as described in Example 2. 0.91 g of white particles containing 5.9 percent (w/w) Mn was obtained.
  • SRRE 2.95 s -1 mM -1 .
  • DTPA was bound to 2.0 g starch gel beads (Example 1, type B) as described in Example 2.
  • the particles were suspended in 50 ml distilled water, the pH-value was adjusted to 6.3 and a solution of 1.25 g FeCl 3 .6H 2 O in 10 ml distilled water was added. The pH-value was adjusted to 5.1 and the suspension was agitated for 1 hour.
  • the particles were purified and isolated as described in Example 2. 1.25 g of dark yellow particles containing 7.8 percent (w/w) Fe were obtained. W r 23.2. T 1/2 >24 h.
  • SRRE 0.52 s -1 mM -1 . D av 1.9 ⁇ m.
  • DTPA was bound to 2.0 g starch gel beads (Example 1, type B) as described in Example 2.
  • the particles were suspended in 50 ml distilled water, the pH-value was adjusted to 6.1 and a solution of 1.72 g GdCl 3 .6H 2 O in 10 ml distilled water was added during agitation, the pH-value was adjusted to 5.2 and the suspension was agitated for 50 minutes.
  • the particles were purified and isolated as described in Example 2. 1.72 g of white particles containing 12.2 per cent (w/w) Gd were obtained. W r 7.4. T1/2>24 h. SRRE 6.4 s -1 mM -1 . D av 1.3 ⁇ m.
  • TTHA triethylenetetraaminehexaacetic acid
  • 4-dimethylaminopyridine a suspension of 2.0 g of starch gel beads (Example 1, type B) in 175 ml dry DMSO.
  • 5.0 g N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide were added and the suspension was agitated for 22 hours at ambient temperature.
  • the agitated reaction mixture was cooled in an ice bath, 100 ml of distilled water were gradually added, the ice bath was removed, the mixture was stirred for 30 minutes and the pH-value was adjusted to 6.5.
  • TTHA was bound to 2.0 g of starch gel beads (Example 1, type B) as described in Example 14.
  • the pH-value was adjusted to 6.5 and a solution of 1.4 g MnCl 2 .4H 2 O in 20 ml distilled water was added. The pH-value was adjusted to 5.7 and the suspension was agitated for 30 minutes. The particles were purified and isolated as described in Example 2. 1.7 g of white particles containing 0.9 per cent (w/w) Mn were obtained. W r 4.6. T 1/2 >24 h. SRRE 4.6 s -1 mM -1 . D av 1.1 ⁇ m.
  • starch gel beads (Example 1, type B) were swelled in 30 ml of distilled water, 1.6 ml of epichlorohydrin and 5.2 ml of 2M NaOH were gradually added during 2 hours while the suspension was shaken at ambient temperature. 9 mg sodium borohydride were added and the suspension was shaken for 24 hours at ambient temperature. The suspension was centrifuged, the supernatant was removed and the particles were washed with distilled water followed by resuspension in 50 ml of distilled water. 2.4 g of 1,6-diaminohexane were added, and the suspension was shaken for 22 hours at ambient temperature. The suspension was centrifuged, the supernatant was removed, the particles were washed with distilled water followed by washing with dry DMF.
  • the particles were resuspended in dry DMF, 5.4 g of the bisanhydride of DTPA were added and the suspension was agitated for 17 hours at ambient temperature.
  • the pH-value was adjusted to 10
  • the suspension was centrifuged, the supernatant was removed and the particles were washed with distilled water.
  • the particles were resuspended in 50 ml of distilled water, the pH-value was adjusted to 6.0, a solution of 0.94 g GdCl 3 .6H 2 O in 20 ml distilled water was added and the pH-value was adjusted to 5.1.
  • the suspension was agitated for 30 minutes, the supernatant was removed and the particles were thoroughly washed with distilled water.
  • the particles were dried in vacuo at 50° C.
  • a solution of 0.6 g 1,1'-carbonyldiimidazole in 15 ml of dry acetone was added to a suspension of 1.0 g of starch gel beads (Example 1, type B) in 20 ml of dry acetone.
  • the suspension was shaken for 20 minutes at ambient temperature, and the solvent was removed after centrifugation.
  • the particles were washed with acetone, resuspended in 50 ml of acetone and 2.3 g of 1,6-diaminohexane were added.
  • the suspension was shaken for 18 hours at ambient temperature, the solvent was removed after centrifugation and the particles were washed with acetone.
  • the particles were resuspended in dry DMF, 1.3 g of the bisanhydride of DTPA were added and the mixture was agitated for 24 hours at ambient temperature. 100 ml of distilled water was added, the pH-value was adjusted to 10 and the suspension was agitated for 30 minutes at ambient temperature. The suspension was centrifuged, the supernatant was removed and the particles were thoroughly washed with distilled water. The particles were resuspended in 30 ml of distilled water, the pH-value was adjusted to 6.1 and a solution of 1.36 g GdCl 3 .6H 2 O in 20 ml distilled water was added. The pH-value was adjusted to 5.3 and the suspension was shaken for 30 minutes followed by centrifugation.
  • the particles were resuspended in 50 ml of distilled water, a solution of 5.7 g of chloroacetic acid in 30 ml distilled water was adjusted to the pH-value of 7.0 with 2M NaOH and 1M NaHCO 3 and the solution was added to the suspension. The suspension was agitated for 17 hours at ambient temperature and the suspension was centrifuged. The supernatant was removed and the particles were thoroughly washed with distilled water.
  • the particles were resuspended in 50 ml of distilled water and the pH-value was adjusted to 6.0. A solution of 0.94 g GdCl 3 .6H 2 O in 20 ml water was added, the pH-value was adjusted to 5.8 and the suspension was agitated for 30 minutes followed by centrifugation. The supernatant was removed and the particles were thoroughly washed with distilled water. The particles were dried in vacuo at 50° C. 1.1 g of white particles containing 2.1 per cent (w/w) Gd were obtained. The particles swell in water. T 1/2 >24 hours. On suspending 30 mg of the particles in 5 ml glycerol:water (1:2.13) (v:v), T 1 was reduced from 1926 ms to 1147 ms. D av 1.5 ⁇ M.
  • a solution of 0.9 g 1,1'-carbonyldiimidazole in 30 ml dry acetone was added to a suspension of 2.0 g starch gel beads (Example 1, type B) in 60 ml of dry acetone.
  • the suspension was agitated for 30 minutes at ambient temperature, centrifuged and the supernatant was removed.
  • the particles were washed with acetone and resuspended in 40 ml of acetone.
  • 2.4 g triethylenetetraamine were added and the suspension was agitated for 20 hours at ambient temperature. The mixture was centrifuged, the supernatant was removed, the particles were first washed with acetone and then with distilled water.
  • the particles were resuspended in 50 ml of distilled water. 3.2 g of bromoacetic acid were added. The pH-value was adjusted to 9.5, the mixture was shaken for 24 hours and 2M NaOH were added in order to keep the pH-value at 7 to 9. The suspension was centrifuged, the supenatant was removed, the particles were washed with distilled water and the particles were resuspended in 50 ml of distilled water. The pH-value was adjusted to 6.0, a solution of 0.8 g of EuCl 3 .6H 2 O in 20 ml of distilled water was added, the pH-value was adjusted to 5.0 and the suspension was agitated for 30 minutes.
  • a solution of 0.9 g 1,1'-carbonyldiimidazole in 30 ml dried acetone was added to a suspension of 2.0 g starch gel beads (Example 1, type B) in 60 ml of dry acetone.
  • the suspension was agitated for 30 minutes at ambient temperature, centrifuged and the supernatant was removed. The particles were washed with acetone and resuspended in 40 ml acetone.
  • 3.9 g pentaethylenehexamine were added and the suspension was agitated for 20 hours at ambient temperature.
  • CM--Sephadex C 25, available from Pharmacia Fine Chemicals AB, Uppsala, Sweden--Sephadex is a registered Trade Mark
  • carboxymethyldextran gel beads C 25, available from Pharmacia Fine Chemicals AB, Uppsala, Sweden--Sephadex is a registered Trade Mark
  • the pH-value was adjusted to 6.0 and a solution of 2.76 g GdCl 3 .6H 2 O in 30 ml distilled water was added during agitation.
  • the pH-value was adjusted to 5.5 and the particles were agitated for 30 minutes. The particles were collected on a filter, washed thoroughly on the filter with 0.9 percent (w/v) NaCl followed by distilled water.
  • dextran gel beads (Sephadex G 50, available from Pharmacia Fine Chemicals AB, Uppsala, Sweden) were swelled in 150 ml distilled water. 0.43 ml of epichlorohydrin and 1.0 ml of triethylamine were added and the suspension was shaken for 24 hours at ambient temperature. The particles were collected on a filter, washed on the filter with distilled water and resuspended in 150 ml distilled water. 3.0 g of polyethyleneamine (Polymin SN, available from Badische Anilin- & Sodafabrik, Ludwigshafen, Federal Republic of Germany--Polymin is a registered Trade Mark) were added and the suspension was shaken for 24 hours at ambient temperature.
  • Polymin SN available from Badische Anilin- & Sodafabrik, Ludwigshafen, Federal Republic of Germany--Polymin is a registered Trade Mark
  • the particles were collected on a filter, washed on the filter with distilled water and resuspended in 150 ml distilled water. 3.4 g of bromoacetic acid were added, the pH-value was adjusted to 9.5 and the suspension was shaken for 24 hours. The particles were collected on a filter, washed on the filter with distilled water, resuspended in 100 ml distilled water and the pH-value was adjusted to 6.3. A solution of 0.75 g GdCl 3 .6H 2 O in 20 ml distilled water was added and the suspension was shaken for 30 minutes at ambient temperature. The particles were collected on a filter, washed thoroughly with distilled water and dried in vacuo at 50° C. 1.7 g of white particles containing 1.3 percent (w/w) Gd were obtained. W r 15.6. SRRE 0.32 s -1 mM -1 . D 25-100 ⁇ m.
  • cross-linked thiolhydroxypropyl gel beads prepared from cross-linked dextran gel beads (Sephadex, G 50, available from Pharmacia Fine Chemicals AB, Uppsala, Sweden) by the method described for thiolhydroxypropylagarose gel beads in Acta Chem. Scand. B 29 (1975) 471-4 by R. Axen, H. Drevin and J. Carlsson] having D av 63 ⁇ m and a thiol group content of 106 ⁇ mol/g were swelled in 50 ml dimethylsulphoxide. After centrifugation 30 ml of dimethylsulphoxide were added.
  • EDTA ethylenediaminetetraacetic acid
  • the activated particles were washed with dry dimethylsulphoxide and suspended in 30 ml of dimethyl sulphoxide. 0.72 g of the bisanhydride of DTPA was added and the mixture shaken for 16 hours. The particles were isolated by centrifugation and 50 ml of distilled water were added. After washing with water 6 times the particles were suspended in 100 ml of distilled water and the pH-value was adjusted to 4.3.
  • cellulose particles (Sigmacell type 20, available from Sigma Chemical Company, St. Louis, U.S.A.--Sigmacell is a registered Trade mark) were suspended in 100 ml of distilled water. 0.43 ml epichlorohydrin and 1.0 ml triethylamine were added and the suspension was shaken for 24 hours at ambient temperature. The particles were collected on a filter, washed on the filter with distilled water and resuspended in 100 ml of distilled water. 3.0 g of diethylenetriamine were added and the suspension was shaken for 24 hours at ambient temperature. The particles were collected on a filter, washed on the filter with distilled water and resuspended in 100 ml of distilled water.
  • 1,4,7,10-Tetraazacyclododecane-N,N',N",N'"-tetraacetic acid was prepared according to the method described in Inorg. Chem. 19 (1980) 1319 by J. F. Desreux, and was reacted with glycine benzylester according to the mixed anhydride method described in Biochem. Biophys. Res. Comm.
  • Example 14 or the carbodiimide method described in Example 14 as follows: 12.8 g DOTA in dried DMSO was carefully added to a solution of 6.7 g N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride and 400 mg N,N-4-dimethylaminopyridine in DMSO. After 30 minutes a solution of 10.6 g of glycine benzylester-p-toluenesulphonate and 3.21 g of N-methylmorpholine was added dropwise during 1 hour. The solution was stirred for 22 hours and lyophilized. The residue was dissolved in water and washed several times with chloroform at pH 2 and 10. The resulting water solution was evaporated and the crude product washed with ethanol/water.
  • Example 1 0.50 g of starch microspheres (Example 1, type E) was suspended and swelled in distilled water. 25 ml of a 0.48 percent (w/v) aqueous solution of KMnO 4 were added slowly with stirring at 60° C. The mixture was stirred for 0.5 h and was left standing overnight. By contact with the carbohydrate KMnO 4 was reduced to a highly dispersed insoluble form of the Mn (IV) oxidation state entrapped in the microspheres and the partial oxidation of the carbohydrate increased the swelling. The particles were separated by centrifugation, washed with distilled water, de-watered with ethanol and dried at 60° C. in vacuo for 36 hours. 0.46 g of particles containing 7.5 percent (w/w) Mn was obtained. W r 14.2. The particles were degradable by amylase. D av 14 ⁇ 8 ⁇ m.
  • SRRE Specific relaxation rate enhancement
  • gadolinium (III) phosphate dextran gel beads 0.50 g was prepared in accordance with Example 35 and suspended in 10 ml of an aqueous solution of 0.9 percent (w/v) NaCl. The suspension was filled in a 10 ml vial and sterilized. The suspension contained 1.0 mg Gd/ml.
  • gadolinium (III) DTPA--starch gel beads was prepared in accordance with Example 13 and suspended in 10 ml of 0.9 percent of a sterile aqueous solution of NaCl. The suspension was filled in a 10 ml vial. The preparation was done aseptically. The isotonic suspension contained 4 mg Gd/ml.
  • gadolinium (III) starch gel beads 0.37 g was prepared in accordance with Example 17 and suspended in 10 ml of 0.9 percent of an aqueous solution of NaCl. The suspension was filled in a 10 ml vial and sterilized. The suspension contains 1 mg Gd/ml.
  • the suspension was filled in a 100 ml bottle.
  • the suspension contained 0.1 mg Fe/ml.
  • the following powder was mixed: 0.77 g of gadolinium (III)--dextran gel beads prepared in accordance with Example 25, 5 g of saccharose and colouring agent q.s.
  • the powder was filled in a 100 ml bottle. When adding 100 ml of water the suspension contains finally 0.1 mg of Gd/ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US06/793,899 1984-11-01 1985-11-01 A diagnostic agent containing a non-radioactive paramagnetic metal species in a macromolecular carrier Expired - Fee Related US4985233A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE8405500 1984-11-01
SE8405501 1984-11-01
SE8405500A SE465908B (sv) 1984-11-01 1984-11-01 Diagnosticeringspartiklar innehaallande en paramagnetisk metall
SE8405501A SE465909B (sv) 1984-11-01 1984-11-01 Partikelformat diagnosticeringsmedel innehaallande en paramagnetisk metall

Publications (1)

Publication Number Publication Date
US4985233A true US4985233A (en) 1991-01-15

Family

ID=26658808

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/793,899 Expired - Fee Related US4985233A (en) 1984-11-01 1985-11-01 A diagnostic agent containing a non-radioactive paramagnetic metal species in a macromolecular carrier

Country Status (6)

Country Link
US (1) US4985233A (fr)
EP (1) EP0184899B1 (fr)
JP (1) JPH0678246B2 (fr)
DE (1) DE3577185D1 (fr)
DK (1) DK164486C (fr)
NO (1) NO169525C (fr)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155215A (en) * 1985-11-18 1992-10-13 Access Pharmaceuticals Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US5154179A (en) * 1987-07-02 1992-10-13 Medical Magnetics, Inc. Device construction and method facilitating magnetic resonance imaging of foreign objects in a body
WO1992022201A1 (fr) * 1991-06-17 1992-12-23 Baxter Diagnostics Inc. Procede de production de particules polymeres a sensibilite magnetique, et application de celui-ci
US5208324A (en) * 1988-01-26 1993-05-04 Nycomed Imaging As Paramagnetic compounds
US5213788A (en) * 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
WO1993010440A1 (fr) * 1991-11-19 1993-05-27 Unger Evan C Substances de contraste a particules de gel destinees a un procede d'imagerie diagnostique ameliore
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5250284A (en) * 1991-10-15 1993-10-05 Arnon Krongrad Method for increasing nuclear magnetic resonance signals in living biological tissue using zinc
US5268165A (en) * 1990-10-16 1993-12-07 Biomedical Frontiers, Inc. Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
WO1994002068A1 (fr) * 1992-07-21 1994-02-03 The General Hospital Corporation Systeme d'administration d'un medicament aux tissus lyphatiques
US5310539A (en) * 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
US5336762A (en) * 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
WO1994017829A1 (fr) * 1993-02-02 1994-08-18 Neorx Corporation Biodistribution dirigee des petites molecules
US5358702A (en) * 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
US5417960A (en) * 1987-04-14 1995-05-23 Guerbet S.A. Nitrogen-containing cyclic ligands, metallic complexes formed by these ligands, diagnostic compositions containing these complexes and process for the preparation of the ligands
US5424419A (en) * 1991-06-11 1995-06-13 Meito Sangyo Kabushiki Kaisha Oxidized complex comprising water-soluble carboxypolysaccharide and magnetic iron oxide
US5532006A (en) * 1993-04-23 1996-07-02 The Board Of Trustees Of The University Of Illinois Magnetic gels which change volume in response to voltage changes for MRI
US5534240A (en) * 1992-02-20 1996-07-09 Meiji Milk Products Company, Ltd. Unchelated manganese composition for MRI of the gastrointestinal tract
US5558857A (en) * 1991-06-03 1996-09-24 Nycomed Imaging As Contrast agents
US5583206A (en) * 1992-10-14 1996-12-10 Sterling Winthrop Chelating polymers
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
US5863518A (en) * 1994-10-21 1999-01-26 Nihon Medi-Physics Co., Ltd. Diagnostic imaging agent with backbone with modified sugar chain end
US5876698A (en) * 1991-05-10 1999-03-02 Schering Aktiengesellschaft Macrocyclic polymer complexing agents, their complexes, process for their production and pharmaceutical agents containing these compounds
US5932188A (en) * 1992-10-14 1999-08-03 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
US6013531A (en) * 1987-10-26 2000-01-11 Dade International Inc. Method to use fluorescent magnetic polymer particles as markers in an immunoassay
US6015545A (en) * 1995-07-11 2000-01-18 Thomsen; Henrik S. Manganese containing magnetic resonance contrast agent
US6122540A (en) * 1994-06-08 2000-09-19 The Regents Of The University Of California Noninvasive measurement of renal hemodynamic functions using magnetic resonance imaging
US6133047A (en) * 1996-05-24 2000-10-17 Bio Merieux Superparamagnetic monodisperse particles
US6139751A (en) * 1996-08-09 2000-10-31 Cooperatie Cosun U.A. Biodegradable complexing agents for heavy metals
US6153172A (en) * 1983-12-21 2000-11-28 Nycomed Imaging As Reflective microspheres for ultrasonic imaging
US6203777B1 (en) * 1983-12-21 2001-03-20 Nycomed Imaging As Method of contrast enhanced magnetic resonance imaging using carbohydrate particles
US6251366B1 (en) * 1992-06-01 2001-06-26 Basf Aktiengesellschaft Use of dispersions of magneto-ionic particles as MRI contrast media
US6468505B1 (en) 1997-04-09 2002-10-22 Philipp Lang Technique to monitor drug delivery noninvasively in vivo
WO2004004786A1 (fr) * 2002-07-02 2004-01-15 Universitair Medisch Centrum Utrecht Suspension de balayage comprenant une particule dont le diametre s'eleve a au moins 1 micrometre
US20040143180A1 (en) * 2001-11-27 2004-07-22 Sheng-Ping Zhong Medical devices visible under magnetic resonance imaging
US20050031543A1 (en) * 1992-01-09 2005-02-10 Amersham Health As Contrast agents
US20050165301A1 (en) * 2004-01-23 2005-07-28 Smith Scott R. Medical devices visible by magnetic resonance imaging
US20050240098A1 (en) * 2004-04-15 2005-10-27 Sheng-Ping Zhong Magnetic resonance imaging of a medical device and proximate body tissue
WO2006006861A1 (fr) * 2004-07-15 2006-01-19 Mark Hans Emanuel Composition et procede d'application d'imagerie medicale aux cavites corporelles
US20060115431A1 (en) * 2002-07-22 2006-06-01 Bracco Imaging S.P.A. Procedures of cellular labelling with paramagnetic complexes for mri applications
US20070003485A1 (en) * 1991-03-28 2007-01-04 Jo Klaveness Contrast agents
US20070032861A1 (en) * 2005-08-08 2007-02-08 Boston Scientific Scimed, Inc. MRI resonator system with stent implant
US20070167735A1 (en) * 2001-11-27 2007-07-19 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US20070239256A1 (en) * 2006-03-22 2007-10-11 Jan Weber Medical devices having electrical circuits with multilayer regions
US7761138B2 (en) 2004-03-12 2010-07-20 Boston Scientific Scimed, Inc. MRI and X-ray visualization
US9034300B2 (en) 2009-10-16 2015-05-19 Giskit B.V. Composition and method for medical imaging of body cavities

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
EP0330801A1 (fr) * 1983-02-08 1989-09-06 Schering Aktiengesellschaft Particules ferromagnétiques, diamagnétiques ou paramagnétiques avantageuses dans le diagnostic et le traitement des maladies
US5352432A (en) * 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
US5219554A (en) 1986-07-03 1993-06-15 Advanced Magnetics, Inc. Hydrated biodegradable superparamagnetic metal oxides
US5342607A (en) * 1986-07-03 1994-08-30 Advanced Magnetics, Inc. Receptor mediated endocytosis type magnetic resonance imaging contrast agents
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4951675A (en) * 1986-07-03 1990-08-28 Advanced Magnetics, Incorporated Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US5284646A (en) * 1986-07-03 1994-02-08 Advanced Magnetics Inc. Hepatocyte specific receptor mediated endocytosis type magnetic resonance imaging contrast agents
FR2612400A1 (fr) * 1987-03-16 1988-09-23 Centre Nat Rech Scient Microcapsules contenant un marqueur radioactif et/ou paramagnetique sous forme de chelate, et leur utilisation dans le domaine de l'imagerie medicale
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
DE3710730A1 (de) * 1987-03-31 1988-10-20 Schering Ag Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
DE3724188C2 (de) * 1987-07-17 1995-05-18 Heinz Dr Gries Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
GB8813144D0 (en) * 1988-06-03 1988-07-06 Nycomed As Compositions
EP0670167A1 (fr) 1988-08-04 1995-09-06 Advanced Magnetics Incorporated Agents diagnostiques de type endocytose induits par récepteur
US5314681A (en) * 1988-12-23 1994-05-24 Nycomed Innovation Ab Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging
GB8916780D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
GB8916782D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
GB8916781D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
US5393525A (en) * 1989-07-21 1995-02-28 Nycomed Imaging As Contrast medium comprising superparamagnetic or ferromagnetic particles capable of increasing viscosity after administration
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
EP0526503B1 (fr) * 1990-04-10 1997-06-04 Imarx Pharmaceutical Corp. Polymeres utilises comme milieux de contraste en imagerie par resonance magnetique
US5236693A (en) * 1990-11-14 1993-08-17 Brigham And Women's Hospital Medical ultrasound contrast agent and method of using same
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
AU663572B2 (en) * 1992-03-27 1995-10-12 Nihon Medi-Physics Co., Ltd. Tetraazacyclododecane derivative and its use
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
WO2002024588A1 (fr) * 2000-09-21 2002-03-28 Glasstech, Inc. Moule de formage articule pour feuilles de verre
US10996218B2 (en) 2008-03-11 2021-05-04 Ournextbaby Llc Methods for chemotaxis / redox driven separation of X and Y chromosome bearing sperm and their insemination in gender specific menstrual cycles
WO2012036691A1 (fr) 2010-09-16 2012-03-22 Urobiologics Llc Utilisation d'urine de mammifère femelle pour la détermination de caractéristiques liées au sexe d'un fœtus

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862920A (en) * 1956-06-07 1958-12-02 Ohio Commw Eng Co Ferrous carboxymethyl dextran
US3495954A (en) * 1966-04-07 1970-02-17 Atomic Energy Authority Uk Precipitation processes for metalcontaining materials
US3563978A (en) * 1968-05-15 1971-02-16 Irving L Ochs Polyvalent metal complexes of natural polymers
US3928581A (en) * 1972-09-13 1975-12-23 Astra Laekemedel Ab Certain polymer-iron complexes for treatment of iron deficiency
WO1978000005A1 (fr) * 1977-06-02 1978-12-07 K H Mosbach Particules magnetiques de polymere
SE7800001L (sv) 1978-01-02 1979-07-03 Odlund Bjorn Alf Ingemar Lastningsmaskin
US4370476A (en) * 1979-07-17 1983-01-25 Usher Thomas C Dextran polycarboxylic acids, ferric hydroxide complexes
AU8633082A (en) * 1981-07-24 1983-01-27 Schering Aktiengesellschaft Paramagnetic complex salts and their use in nmr- diagnostics
US4423158A (en) * 1983-01-27 1983-12-27 Gelinnovation Handelsaktiebolag Ion adsorbent for metals having a coordination number greater than two
WO1984000020A1 (fr) * 1982-06-16 1984-01-05 Afit Iv Sz Autojavito Vallalat Dispositif de blocage du levier du frein a main de voiture
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
SE8400437L (sv) 1983-02-18 1984-08-19 Dansk Gartneri Tek As Fordragningsmekanism for under ett tak i rad upphengda gardinpartier
GB2137612A (en) * 1983-01-21 1984-10-10 Schering Ag Metal complex salts and their use in diagnostic preparations
GB8500234D0 (en) 1984-09-04 1985-02-13 Plibrico Japan Co Ltd Wear-resistant refractory lining anchor
EP0135125A2 (fr) * 1983-08-12 1985-03-27 E.I. Du Pont De Nemours And Company Procédé de formation d'images par résonance magnétique nucléaire utilisant des réactifs à déplacement chimique
EP0136812A2 (fr) * 1983-08-25 1985-04-10 Technicare Corporation Réactifs pour l'augmentation du contraste dans la formation d'images par résonance magnétique nucléaire
WO1985002772A1 (fr) * 1983-12-21 1985-07-04 Schroeder Ulf Agent de contraste et de diagnostic
EP0160552A2 (fr) * 1984-04-27 1985-11-06 Vestar, Inc. Agents de contraste pour la formation d'images par résonance magnétique nucléaire
WO1985005554A1 (fr) * 1984-05-31 1985-12-19 Amersham International Plc Agents de contraste pour la resonance magnetique nucleaire
US4615879A (en) * 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1244082A (fr) * 1983-01-10 1988-11-01 Robert T. Gordon Methode pour ameliorer l'image obtenue par rmn et application au diagnostic
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862920A (en) * 1956-06-07 1958-12-02 Ohio Commw Eng Co Ferrous carboxymethyl dextran
US3495954A (en) * 1966-04-07 1970-02-17 Atomic Energy Authority Uk Precipitation processes for metalcontaining materials
US3563978A (en) * 1968-05-15 1971-02-16 Irving L Ochs Polyvalent metal complexes of natural polymers
US3928581A (en) * 1972-09-13 1975-12-23 Astra Laekemedel Ab Certain polymer-iron complexes for treatment of iron deficiency
WO1978000005A1 (fr) * 1977-06-02 1978-12-07 K H Mosbach Particules magnetiques de polymere
SE7800001L (sv) 1978-01-02 1979-07-03 Odlund Bjorn Alf Ingemar Lastningsmaskin
US4370476A (en) * 1979-07-17 1983-01-25 Usher Thomas C Dextran polycarboxylic acids, ferric hydroxide complexes
AU8633082A (en) * 1981-07-24 1983-01-27 Schering Aktiengesellschaft Paramagnetic complex salts and their use in nmr- diagnostics
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
WO1984000020A1 (fr) * 1982-06-16 1984-01-05 Afit Iv Sz Autojavito Vallalat Dispositif de blocage du levier du frein a main de voiture
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
GB2137612A (en) * 1983-01-21 1984-10-10 Schering Ag Metal complex salts and their use in diagnostic preparations
US4423158A (en) * 1983-01-27 1983-12-27 Gelinnovation Handelsaktiebolag Ion adsorbent for metals having a coordination number greater than two
SE8400437L (sv) 1983-02-18 1984-08-19 Dansk Gartneri Tek As Fordragningsmekanism for under ett tak i rad upphengda gardinpartier
EP0135125A2 (fr) * 1983-08-12 1985-03-27 E.I. Du Pont De Nemours And Company Procédé de formation d'images par résonance magnétique nucléaire utilisant des réactifs à déplacement chimique
EP0136812A2 (fr) * 1983-08-25 1985-04-10 Technicare Corporation Réactifs pour l'augmentation du contraste dans la formation d'images par résonance magnétique nucléaire
US4615879A (en) * 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
WO1985002772A1 (fr) * 1983-12-21 1985-07-04 Schroeder Ulf Agent de contraste et de diagnostic
EP0160552A2 (fr) * 1984-04-27 1985-11-06 Vestar, Inc. Agents de contraste pour la formation d'images par résonance magnétique nucléaire
WO1985005554A1 (fr) * 1984-05-31 1985-12-19 Amersham International Plc Agents de contraste pour la resonance magnetique nucleaire
GB8500234D0 (en) 1984-09-04 1985-02-13 Plibrico Japan Co Ltd Wear-resistant refractory lining anchor
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Concise Encyclopedia of Chemical Technology, pp. 55 56 (1988) *
Concise Encyclopedia of Chemical Technology, pp. 55-56 (1988)
Desreux, Inorg. Chem., vol 19 (1980), pp. 1319 1324. *
Desreux, Inorg. Chem., vol 19 (1980), pp. 1319-1324.
High Resolution NMR, Acadm. Press 1980, Becker, pp. 48 51. *
High Resolution NMR, Acadm. Press 1980, Becker, pp. 48-51.
Structure of An Iron Dextran Complex, J. Pharm. Pharmac. 1972, 24, pp. 513 517, Cox et al. *
Structure of An Iron-Dextran Complex, J. Pharm. Pharmac. 1972, 24, pp. 513-517, Cox et al.
The Merck Index, 9th Ed. 1976, p. 2911. *
Work In Progress: Potential Oral and Intravenous Paramagnetic NMR Contrast Agents, RADIOLOGY, vol. 147, No. 3, Jul. 83, Runge et al., pp. 789 791. *
Work In Progress: Potential Oral and Intravenous Paramagnetic NMR Contrast Agents, RADIOLOGY, vol. 147, No. 3, Jul.'83, Runge et al., pp. 789-791.

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203777B1 (en) * 1983-12-21 2001-03-20 Nycomed Imaging As Method of contrast enhanced magnetic resonance imaging using carbohydrate particles
US6153172A (en) * 1983-12-21 2000-11-28 Nycomed Imaging As Reflective microspheres for ultrasonic imaging
US5336762A (en) * 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US5155215A (en) * 1985-11-18 1992-10-13 Access Pharmaceuticals Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US5417960A (en) * 1987-04-14 1995-05-23 Guerbet S.A. Nitrogen-containing cyclic ligands, metallic complexes formed by these ligands, diagnostic compositions containing these complexes and process for the preparation of the ligands
US5154179A (en) * 1987-07-02 1992-10-13 Medical Magnetics, Inc. Device construction and method facilitating magnetic resonance imaging of foreign objects in a body
US6013531A (en) * 1987-10-26 2000-01-11 Dade International Inc. Method to use fluorescent magnetic polymer particles as markers in an immunoassay
US5208324A (en) * 1988-01-26 1993-05-04 Nycomed Imaging As Paramagnetic compounds
US5213788A (en) * 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
US5976500A (en) * 1990-04-10 1999-11-02 Imarx Pharmaceutical Corp. Gel particle contrast media for magnetic resonance imaging
US5358702A (en) * 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5268165A (en) * 1990-10-16 1993-12-07 Biomedical Frontiers, Inc. Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
US20070003485A1 (en) * 1991-03-28 2007-01-04 Jo Klaveness Contrast agents
US5310539A (en) * 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
US5876698A (en) * 1991-05-10 1999-03-02 Schering Aktiengesellschaft Macrocyclic polymer complexing agents, their complexes, process for their production and pharmaceutical agents containing these compounds
US5558857A (en) * 1991-06-03 1996-09-24 Nycomed Imaging As Contrast agents
US5569449A (en) * 1991-06-03 1996-10-29 Nycomed Imaging As Gaseous microparticles as ultrasound contrast agents
US5424419A (en) * 1991-06-11 1995-06-13 Meito Sangyo Kabushiki Kaisha Oxidized complex comprising water-soluble carboxypolysaccharide and magnetic iron oxide
AU654381B2 (en) * 1991-06-17 1994-11-03 Dade Behring Inc. Process for producing magnetically responsive polymer particles and application thereof
WO1992022201A1 (fr) * 1991-06-17 1992-12-23 Baxter Diagnostics Inc. Procede de production de particules polymeres a sensibilite magnetique, et application de celui-ci
US5250284A (en) * 1991-10-15 1993-10-05 Arnon Krongrad Method for increasing nuclear magnetic resonance signals in living biological tissue using zinc
WO1993010440A1 (fr) * 1991-11-19 1993-05-27 Unger Evan C Substances de contraste a particules de gel destinees a un procede d'imagerie diagnostique ameliore
US20050196342A1 (en) * 1992-01-09 2005-09-08 Jo Klaveness Contrast agents
US20050031543A1 (en) * 1992-01-09 2005-02-10 Amersham Health As Contrast agents
US5534240A (en) * 1992-02-20 1996-07-09 Meiji Milk Products Company, Ltd. Unchelated manganese composition for MRI of the gastrointestinal tract
US6251366B1 (en) * 1992-06-01 2001-06-26 Basf Aktiengesellschaft Use of dispersions of magneto-ionic particles as MRI contrast media
US5582172A (en) * 1992-07-21 1996-12-10 The General Hospital Corporation System of drug delivery to the lymphatic tissues
WO1994002068A1 (fr) * 1992-07-21 1994-02-03 The General Hospital Corporation Systeme d'administration d'un medicament aux tissus lyphatiques
US5932188A (en) * 1992-10-14 1999-08-03 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
US5583206A (en) * 1992-10-14 1996-12-10 Sterling Winthrop Chelating polymers
US5607659A (en) * 1993-02-02 1997-03-04 Neorx Corporation Directed biodistribution of radiolabelled biotin using carbohydrate polymers
WO1994017829A1 (fr) * 1993-02-02 1994-08-18 Neorx Corporation Biodistribution dirigee des petites molecules
US5532006A (en) * 1993-04-23 1996-07-02 The Board Of Trustees Of The University Of Illinois Magnetic gels which change volume in response to voltage changes for MRI
US6122540A (en) * 1994-06-08 2000-09-19 The Regents Of The University Of California Noninvasive measurement of renal hemodynamic functions using magnetic resonance imaging
US5863518A (en) * 1994-10-21 1999-01-26 Nihon Medi-Physics Co., Ltd. Diagnostic imaging agent with backbone with modified sugar chain end
US6015545A (en) * 1995-07-11 2000-01-18 Thomsen; Henrik S. Manganese containing magnetic resonance contrast agent
US6133047A (en) * 1996-05-24 2000-10-17 Bio Merieux Superparamagnetic monodisperse particles
US6139751A (en) * 1996-08-09 2000-10-31 Cooperatie Cosun U.A. Biodegradable complexing agents for heavy metals
US6468505B1 (en) 1997-04-09 2002-10-22 Philipp Lang Technique to monitor drug delivery noninvasively in vivo
US20040143180A1 (en) * 2001-11-27 2004-07-22 Sheng-Ping Zhong Medical devices visible under magnetic resonance imaging
US20070167735A1 (en) * 2001-11-27 2007-07-19 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US8163326B2 (en) 2001-11-27 2012-04-24 Boston Scientific Scimed, Inc. Implantable or insertable medical devices visible under magnetic resonance imaging
US20050201940A1 (en) * 2002-07-02 2005-09-15 Universitair Medisch Centrum Utrecht Scanning suspension comprising a particle with a diameter of at least 1 micrometer
WO2004004786A1 (fr) * 2002-07-02 2004-01-15 Universitair Medisch Centrum Utrecht Suspension de balayage comprenant une particule dont le diametre s'eleve a au moins 1 micrometre
US9731037B2 (en) 2002-07-02 2017-08-15 Universitair Medisch Centrum Utrecht Scanning suspension comprising a particle with a diameter of at least 1 micrometer
US8632751B2 (en) 2002-07-02 2014-01-21 Universitair Medisch Centrum Utrecht Scanning suspension comprising a particle with a diameter of at least 1 micrometer
US20060115431A1 (en) * 2002-07-22 2006-06-01 Bracco Imaging S.P.A. Procedures of cellular labelling with paramagnetic complexes for mri applications
US20050165301A1 (en) * 2004-01-23 2005-07-28 Smith Scott R. Medical devices visible by magnetic resonance imaging
US8620406B2 (en) 2004-01-23 2013-12-31 Boston Scientific Scimed, Inc. Medical devices visible by magnetic resonance imaging
US7761138B2 (en) 2004-03-12 2010-07-20 Boston Scientific Scimed, Inc. MRI and X-ray visualization
US20050240098A1 (en) * 2004-04-15 2005-10-27 Sheng-Ping Zhong Magnetic resonance imaging of a medical device and proximate body tissue
US7483732B2 (en) 2004-04-15 2009-01-27 Boston Scientific Scimed, Inc. Magnetic resonance imaging of a medical device and proximate body tissue
WO2006006861A1 (fr) * 2004-07-15 2006-01-19 Mark Hans Emanuel Composition et procede d'application d'imagerie medicale aux cavites corporelles
US20080286206A1 (en) * 2004-07-15 2008-11-20 Gynaecologiq B.V. Composition and Method for Medical Imaging of Body Cavities
US8992887B2 (en) 2004-07-15 2015-03-31 Gynaecologiq B.V. Method for medical imaging of body cavities
US9717805B2 (en) 2004-07-15 2017-08-01 Gynaecologiq B.V. Composition and method for medical imaging or body cavities
US7778684B2 (en) 2005-08-08 2010-08-17 Boston Scientific Scimed, Inc. MRI resonator system with stent implant
US20070032862A1 (en) * 2005-08-08 2007-02-08 Jan Weber Medical devices
US20070032861A1 (en) * 2005-08-08 2007-02-08 Boston Scientific Scimed, Inc. MRI resonator system with stent implant
US20070239256A1 (en) * 2006-03-22 2007-10-11 Jan Weber Medical devices having electrical circuits with multilayer regions
US9034300B2 (en) 2009-10-16 2015-05-19 Giskit B.V. Composition and method for medical imaging of body cavities
US9259494B2 (en) 2009-10-16 2016-02-16 Giskit B.V. Composition and method for medical imaging of body cavities
US9849199B2 (en) 2009-10-16 2017-12-26 Giskit B.V. Composition and method for medical imaging of body cavities

Also Published As

Publication number Publication date
DK164486B (da) 1992-07-06
JPH0678246B2 (ja) 1994-10-05
EP0184899A1 (fr) 1986-06-18
DE3577185D1 (de) 1990-05-23
EP0184899B1 (fr) 1990-04-18
DK164486C (da) 1992-11-23
NO169525B (no) 1992-03-30
NO169525C (no) 1992-07-08
JPS61155338A (ja) 1986-07-15
DK500085D0 (da) 1985-10-31
DK500085A (da) 1986-05-02
NO854349L (no) 1986-05-02

Similar Documents

Publication Publication Date Title
US4985233A (en) A diagnostic agent containing a non-radioactive paramagnetic metal species in a macromolecular carrier
US4986980A (en) Water-soluble, carrier-bound paramagnetic metal containing diagnostic agents
RU2081881C1 (ru) Макромолекулярное парамагнитное соединение, способ получения макромолекулярного парамагнитного соединения, диагностическое контрастное средство, способ получения диагностического контрастного средства
EP0627632B1 (fr) Compositions pour augmenter le contraste d'images dans des examens du tract digestif de patients
JP4280304B2 (ja) 造影剤
US4827945A (en) Biologically degradable superparamagnetic materials for use in clinical applications
US5155215A (en) Polychelating agents for image and spectral enhancement (and spectral shift)
US4951675A (en) Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
US5219554A (en) Hydrated biodegradable superparamagnetic metal oxides
US5336762A (en) Polychelating agents for image and spectral enhancement (and spectral shift)
US20060251580A1 (en) Lectin conjugates
JPH08501097A (ja) 臨床診断及び治療用部分を含む生体適合性ポリマー
WO1999055230A1 (fr) Agents d'imagerie a base de hyaluronan
Rongved et al. Polysaccharides as carriers for magnetic resonance imaging contrast agents: synthesis and stability of a new amino acid linker derivative
AU623901B2 (en) Paramagnetic compounds comprising chelating moiety, linker group macro molecule and paramagnetic metal
SE465908B (sv) Diagnosticeringspartiklar innehaallande en paramagnetisk metall

Legal Events

Date Code Title Description
AS Assignment

Owner name: NYEGAARD & CO. A/S, NYECOVEIEN 2, OSLO, NORWAY, A

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KLAVENESS, JO;JACOBSEN, TROND;LINDBERG, BERNT J.;REEL/FRAME:004509/0492;SIGNING DATES FROM 19851023 TO 19851029

AS Assignment

Owner name: NYCOMED IMAGING AS, NORWAY

Free format text: CERTIFICATE OF REGISTRATION REFLECTING CHANGE OF NAME;ASSIGNOR:NYCOMED AS;REEL/FRAME:006290/0981

Effective date: 19920910

Owner name: NYCOMED AS, NORWAY

Free format text: CHANGE OF NAME;ASSIGNOR:NYEGAARD & CO AS;REEL/FRAME:006290/0978

Effective date: 19910523

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20030115